Active Ingredient History
Ifetroban is a potent and selective thromboxane receptor antagonist. It has been studied in animal models for the treatment of cancer metastasis, myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy, and for its effects on platelets. Clinical trials are evaluating the therapeutic safety and efficacy of oral ifetroban capsules for the treatment of cancer metastasis, cardiovascular disease, aspirin exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Asthma (Phase 2)
Asthma, Aspirin-Induced (Phase 2)
Autoimmune Diseases (Phase 2)
Cardiomyopathy, Dilated (Phase 2)
Cardiovascular Diseases (Phase 2)
Connective Tissue Diseases (Phase 2)
Hepatorenal Syndrome (Phase 2)
Hypertension, Portal (Phase 2)
Liver Cirrhosis (Phase 2)
Lung Diseases (Phase 2)
Muscular Dystrophy, Duchenne (Phase 2)
Nasal Polyps (Phase 2)
Neoplasms (Phase 2)
Pathologic Processes (Phase 2)
Scleroderma, Diffuse (Phase 2)
Scleroderma, Limited (Phase 2)
Scleroderma, Systemic (Phase 2)
Skin Diseases (Phase 2)
Vascular Diseases (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue